Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 7/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25935462 | 1.00 | HDAC4 (0.52) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25332163 | 0.84 | HRH3 (0.42) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25332170 | 0.84 | HRH3 (0.42) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25934624 | 0.82 | HDAC4 (0.49) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL25934630 | 0.82 | HDAC4 (0.49) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL29360087 | 0.82 | HDAC4 (0.49) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL3496030 | 0.82 | SIRT5 (0.48) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL3496034 | 0.82 | SIRT5 (0.48) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL2604466 | 0.82 | SIRT5 (0.50) | HDAC4HDAC1HDAC8HDAC6HDAC3 | |
| SCHEMBL21585117 | 0.81 | CA2 (0.56) | HDAC4HDAC1HDAC8CA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4469090-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | Genentech Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118591393-A | Antibody conjugated chemical degradation inducers with hydrolyzable maleimide linkers and methods thereof | 基因泰克公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147328-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064968-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION WITH HYDOLYSABLE MALEIMIDE LINKERS AND METHODS THEREOF | LGMN, B2M, HNMT | HDAC4 1289/4885HDAC1 448/4885HDAC8 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.